Background/Aims: The reappearance rates of hepatitis C virus (HCV) RNA after a sustained virological response (SVR) have been reported to be 1-2%. We investigated the reappearance rate of HCV RNA after SVR in chronic hepatitis C (CHC) patients treated with pegylated interferon (PEG-IFN) and ribavirin. Methods: In total, 292 CHC patients who achieved an SVR after PEG-IFN and ribavirin treatment were included. They were treated with subcutaneous injections of either PEG-IFN-α 2a or 2b plus ribavirin orally. Liver function tests and qualitative HCV RNA assays were performed every 6 months during the follow-up period after an SVR. Results: Among the 292 patients, 224 (genotype 1, 92; genotype non-1, 132) were followed up for more than 6 months after SVR. These 224 patients were aged 48.1±11.5 years (mean±SD), and 129 of them were male. The median follow-up duration was 18 months (range 6-60 months). The reappearance rate of HCV RNA during follow-up was 0%. Two patients who achieved an SVR developed hepatocellular carcinoma during the follow-up period. Conclusions: An SVR was maintained in all CHC patients treated with PEG-IFN plus ribavirin during a median follow-up of 18 months. However, a screening test for hepatocellular carcinoma is needed for patients with an SVR. (Korean J Hepatol 2011;17:183-188)
INTRODUCTION
Globally, it has been estimated that 170 million people are chronically infected with the hepatitis C virus (HCV), and 3 to 4 million are infected each year.
1,2 The HCV is a major public health problem and a leading cause of chronic liver disease. 3 Natural history studies indicate that 55% to 85% of individuals who develop acute hepatitis C will remain HCV-infected. [4] [5] [6] The risk of developing cirrhosis ranges from 5% to 25% over periods of 25 to 30 years. 7, 8 The currently recommended therapy for chronic HCV infection is the combination of pegylated interferon (PEG-IFN) and ribavirin. 9 The sustained virological response (SVR) rates in patients treated with PEG-IFN and ribavirin are 50% in HCV genotype 1 and 80-90% in HCV genotype 2 or 3. [9] [10] [11] [12] The achievement of the SVR in patients with chronic hepatitis C (CHC) has been associated with improvements in liver histology as well as a reduced risk of hepatocellular carcinoma (HCC) and liver-related mortality. [13] [14] [15] Previous studies reported that the SVR after PEG-IFN and ribavirin combination therapy was maintained up to 99-100% during the long-term follow-up. [16] [17] [18] [19] [20] However, a Korean study recently reported that the reappearance rate of HCV RNA after SVR was as high as 11%. 21 Therefore, we investigated the reappearance rate of HCV RNA after SVR in CHC patients treated with PEG-IFN and ribavirin. tests for more than 6 months after SVR were 224. Sixty five patients were lost to follow-up. The remaining three patients were less than 6 months of follow-up period, so they didn't perform HCV RNA assays. These 224 patients were actually followed-up for a median period of 18 months (range 6-60 months). The baseline characteristics and treatment doses of the patients were shown in follow-up period (Fig. 1) . If SVR was achieved, there was no relationship between reappearance and the dose of either PEG-IFN or ribavirin. There were two patients who achieved the SVR but developed HCC during the follow-up period. Among them, one had liver cirrhosis before the treatment, the other patients with HCC was a 54-year-old heavy alcoholic. He did not have liver cirrhosis radiologically, but his aspartate aminotransferase-to-platelet ratio index (APRI) was 1.0 (Table 2 ). Figure 2 shows the numbers of patients who were followed up after SVR and the durability. SVR was maintained in all patients during the follow-up period, therefore there was no control group who had a reappearance.
PATIENTS AND METHODS

Patients and treatments
DISCUSSION
The standard therapy for HCV infection is the combination of PEG-IFN and ribavirin. According to previous studies, SVR was maintained up to 99-100%, and the achievement of the SVR was considered as cure. (ABI prism system, Applied Biosystems, USA). 21 However, the RT-PCR assay using the ABI prism system was used only in the past 5 years, hence in patients who were treated earlier, the HCV may be quantitatively measured by the HCV RNA assay with lower sensitivity and higher limit of detection than RT-PCR assay using ABI prism system. Therefore, some patients who had small quantities of HCV RNA, which could be detected with the current sensitive HCV RNA assay, may be assessed that they achieved the SVR. Then, if the HCV RNA assay with higher ALT, alanine aminotransferase; APRI, aspartate aminotransferaseto-platelet ratio index; BMI, body mass index; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; RVR, rapid virological response; SVR, sustained virological response. Figure 2 . Durability of the SVR in the CHC patients treated with PEG-IFN plus ribavirin. The numbers in parentheses represent the numbers of patients who were followed up, which was 224 for a median duration of 18 months (range 6-60 months). The SVR was maintained in 100% of the patients during the follow-up.
sensitivity was used during the follow-up period, the HCV RNA could probably be detected in serum. This may be the cause for the higher reappearance rate detected in that study, compared to previous studies. Among the 8 patients who had reappearance of HCV in that study, only one patient had persistent viremia, 5
patients had transiently positive HCV RNA, and 2 patients were followed-up. 21 It is possible that the transiently positive HCV RNA result may be false positive. Therefore, the reappearance rate can be considered as 1.4% (1/73). In a recent study, transient low levels of HCV RNA at single time points were detected in some serum samples during the follow-up, but they were all undetectable on retests. 19 Therefore, the authors reported that these transient positive tests probably represented false positive results. 20 In our study, we also experienced one transient postive HCV RNA result which was undetectable on retest. It is not known whether patients who become HCV RNA detectable during follow-up experienced reinfection or reappearance.
Another Korean study recently reported that the reappearance rate after SVR was 7.4% (5/68). This higher reappearance rate also may be due to using HCV RNA assay with lower sensitivity in early treatment period.
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In our study, among the 292 patients who achieved the SVR in response to PEG-IFN and ribavirin combination therapy, 224
were followed up for a median period of 18 months (range 6-60 months). SVR was maintained in all patients (n=224, 100%),
including patients who were treated with decreased doses of PEG-IFN or ribavirin, therefore the durability of SVR was as high as in previous studies. When patients were treated with decreased doses of PEG-IFN or ribavirin, they had lower SVR. 23 After achievement of the SVR, however, we found no relationship between the treatment dose and reappearance. This suggests that, after achievement of the SVR, intensive follow-up is not needed in patients treated with lower doses of PEG-IFN or ribavirin than in patients who received sufficient doses.
In patients with CHC, achievement of the SVR has been associated with improvements in liver histology, as well as reduced risk of HCC and liver-related mortality. Similarly, in patients with HCV-related cirrhosis, achievement of the SVR after IFN therapy was associated with reduction of liver-related mortality lowering both the risk of complications and HCC development. [13] [14] [15] [24] [25] [26] However, in patients with advanced fibrosis or cirrhosis, achievement of the SVR cannot prevent completely the risk of HCC. 23, 27, 28 In our study, there were two patients who achieved the SVR but developed HCC during the follow-up period. Among them, one had liver cirrhosis before the treatment, so liver may undergo irreversible changes, leading to an elevated risk for carcinogenesis even when the HCV RNA has been disappeared in serum.
The other patient was a alcoholic and showed APRI 1.0 that might suggest hepatic fibrosis. Thus, significant fibrosis and persistent liver damage due to alcohol were thought to be To summarize, previous studies reported that SVR after PEG-IFN and ribavirin combination therapy was maintained up to 99-100% during the long-term follow-up. [16] [17] [18] [19] [20] Our study
showed that SVR was durable in all the CHC patients for a median follow-up of 18 months. However, screening test for HCC should be needed in the patients with SVR, particularly advanced fibrosis or cirrhosis.
